Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Grand Pharmaceutical Group Limited (0512) Stock Price & Analysis

5 Followers

0512 Stock Chart & Stats

HK$4.43-HK$0.00(-0.45%)
At close: 4:00 PM GMT+8
HK$4.5HK$5HK$5.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 4.40 - HKD 4.52
52-Week Range
HKD 4.14 - HKD 8.84
Previous Close
HKD 4.45
Volume
N/A
Average Volume (3M)
2.99M
Market Cap
HKD 15.72B
Enterprise Value
HKD 20.34B
Total Cash (Recent Filing)
HKD 1.27B
Total Debt (Recent Filing)
HKD 5.05B
Price to Earnings (P/E)
13.8
Beta
0.70
Next Earnings
Mar 17, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Jun 12, 2026
Dividend Yield
3.81%

Bulls Say, Bears Say

Bulls Say

Resilient Revenue Growth

Steady revenue expansion indicates continued demand for the company’s pharmaceutical and medical products despite weaker profitability. A growing top line supports scale, distribution reach, and ongoing investment in products and capabilities over the next several quarters.

Moderate Leverage

Moderate and stable leverage gives the company greater financial flexibility than a highly indebted peer. The balance sheet can better absorb operating volatility while preserving capacity to fund development, manufacturing, commercialization, and other strategic priorities.

Positive Free Cash Flow

Continued positive free cash flow provides an internal source of funding for operations and investment, reducing reliance on external financing. Although conversion weakened, ongoing cash generation remains a useful foundation for maintaining the business and supporting future product activity.

Bears Say

Material Margin Compression

The sharp decline in net and operating margins shows that revenue growth is currently translating into substantially less profit. If this pressure persists, it can reduce reinvestment capacity, weaken earnings quality, and make future growth less valuable to shareholders.

Weaker Cash Conversion

Lower operating cash flow and reduced free-cash-flow conversion indicate that accounting earnings are generating less cash than before. This weakens funding flexibility and could constrain the company’s ability to invest, return capital, or absorb further operating pressure.

Earnings Decline

The pronounced decline in earnings per share signals that recent business growth has not protected shareholder earnings power. Persistent earnings contraction could limit internal compounding, reduce the ability to support distributions, and increase dependence on a recovery in profitability.

Grand Pharmaceutical Group Limited News

0512 FAQ

What was Grand Pharmaceutical Group Limited’s price range in the past 12 months?
Grand Pharmaceutical Group Limited lowest stock price was HK$4.14 and its highest was HK$8.84 in the past 12 months.
What is Grand Pharmaceutical Group Limited’s market cap?
Grand Pharmaceutical Group Limited’s market cap is HK$15.72B.
When is Grand Pharmaceutical Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Grand Pharmaceutical Group Limited’s earnings last quarter?
Grand Pharmaceutical Group Limited released its earnings results on Aug 26, 2026. The company reported HK$0.278 earnings per share for the quarter.
Is Grand Pharmaceutical Group Limited overvalued?
According to Wall Street analysts Grand Pharmaceutical Group Limited’s price is currently Undervalued.
Does Grand Pharmaceutical Group Limited pay dividends?
Grand Pharmaceutical Group Limited pays an annual dividend of HK$0.169 which represents an annual dividend yield of 3.81%. See more information on Grand Pharmaceutical Group Limited dividends here
What is Grand Pharmaceutical Group Limited’s EPS estimate?
Grand Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grand Pharmaceutical Group Limited have?
Grand Pharmaceutical Group Limited has 3,549,571,000 shares outstanding.
What happened to Grand Pharmaceutical Group Limited’s price movement after its last earnings report?
Grand Pharmaceutical Group Limited reported an EPS of HK$0.278 in its last earnings report. Following the earnings report the stock price went up 0.379%.
Which hedge fund is a major shareholder of Grand Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:0512
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology